Browse

Treeline Biosciences has shared plans to debut on public markets through a reverse merger with Standard BioTools in a move that should give the company a cash runway through 2029. The

At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

Johnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a preclinical startup working on degrader antibody conjugates. J&J now joins th…